HARBOUR BIOMED

?? Join the "Globalization Practice Pioneer" Employer ?? Unlock the Superpowers of an AI+ Global Workplace

?? HARBOUR BIOMED and Insilico Medicine Announce Strategic Collaboration to Advance AI-Driven Antibody Discovery ?? We’re thrilled to announce a strategic collaboration with Insilico Medicine to accelerate the discovery and development of innovative therapeutic antibodies! By combining our industry-leading Harbour Mice? platform, proprietary dataset, and deep expertise in antibody development with Insilico’s cutting-edge AI-driven drug discovery technologies, we aim to develop the next-generation AI-powered antibody application, and deliver innovative antibody therapies for immunology, oncology, and neuroscience. As we continue to leverage the strengths of both companies, we’re excited about the future of AI-powered antibody discovery and the impact these next-generation therapies will have. Stay in tuned as we continue to drive innovation in therapeutic antibody development! Learn more: https://lnkd.in/gx3bJMFi #AI #AntibodyDiscovery #Immunology #Oncology #Neurosciences #Innovation

We are pleased to report our strong business progress, with total profit for 2024 expected to range between RMB7.3 million and RMB22 million. The company also achieved a record-high cash profit of RMB220 million, reflecting solid financial health and operational efficiency. ???? The company’s sustained profitability was primarily driven by: ??The accelerated growth of its unique business model with continued strategic partnerships with global pharmaceutical and leading biotech companies. ??A growing recurring component of its revenue in 2024, including platform-based research revenue and milestone payments as collaboration programs advance. ??Effective cost control and efficient operational management. In 2025, the company has repurchased 8,146,000 shares in the open market, amounting to nearly HK$30 million, which reflects confidence in its business outlook. ?? Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed, commented: “Harbour BioMed is accelerating its transformation into a sustainably profitable global biotech engine, driven by our proprietary Harbour Mice? platform and differentiated business model. With more than 19 molecules progressing into the IND stage globally through partnerships with multinational pharmaceutical and biotech companies, our platform’s value continues to be validated. Our strong financial performance highlights the resilience and scalability of our business. Looking ahead, we remain committed to advancing next-generation antibody technologies to address critical medical needs and deliver long-term value to our stakeholders.” Learn more: https://lnkd.in/gMtNY7nd #HarbourBioMed #Innovation #FinancialGrowth

We are pleased to share that the National Medical Products Administration (NMPA) of China has approved the IND application for HBM9378/SKB378 (also known as WIN378), a fully human antibody targeting TSLP, for the treatment of chronic obstructive pulmonary disease (COPD). COPD is a progressive respiratory condition that poses serious health risks and a growing burden on healthcare systems. HBM9378/SKB378 is designed to inhibit TSLP-mediated signaling pathway, aiming to reduce airway inflammation and improve lung function in COPD patients. This regulatory milestone represents an important step forward in addressing the unmet needs in immunological diseases. We believe that HBM9378/SKB378, with its potential best-in-class, long-acting profile and exceptional biophysical properties, will bring meaningful benefits to patients worldwide. Learn more: https://lnkd.in/g_Ddxs7C #HarbourMice #COPD #ClinicalResearch #TSLP

?? We are excited to announce a license agreement with Windward Bio for HBM9378/SKB378, a fully human anti-TSLP monoclonal antibody co-developed with Kelun-Biotech. This partnership highlights the therapeutic potential of HBM9378/SKB378 for immunological diseases and reflects the value of our Harbour Mice? technology platform. Under the agreement, we are eligible for $45 million in upfront and near-term milestone payments, including both cash payment and an equity interest in Windward Bio’s parent company, a total of up to $970 million in upfront and milestone payments, as well as tiered royalties ranging from single to double digits on net sales. Furthermore, we are eligible to receive additional payments if Windward Bio undergoes a near-term change of control or enters into a sublicense agreement with a third party. In connection with the license agreement, Windward Bio announced a $200 million Series A financing round led by OrbiMed, Novo Holdings, and Blue Owl Healthcare Opportunities, along with co-investors SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, and Pivotal bioVenture Partners. We believe Windward Bio's financing will further enable the advancement of this innovative therapy. We look forward to collaborating with Windward Bio to deliver transformative treatments to patients worldwide! Learn more: https://lnkd.in/gNGq_iM7 #HarbourMice #TSLP #immunology

This festival season, we extend our heartfelt wishes for a joyful Christmas and a New Year filled with peace, health, and happiness. May this time bring moments of celebration and reflection for you and your loved ones. ?? ?? We are deeply grateful to our employees, partners and the community for your unwavering trust and support in advancing innovative therapies throughout 2024. Together, we’ve taken meaningful strides toward addressing critical unmet medical needs in immunology and oncology. ? ?? As we approach 2025, we look forward to continuing this journey with you – working together to transform scientific breakthroughs into impact solutions for patients worldwide. Thank you for being an integral part of our story! ?? ?? #HarbourBioMed #Innovation #Collaboration

We’re pleased to welcome Dr. Raymond Zheng as Harbour BioMed’s new Chief Business Officer. Based in the U.S., Dr. Zheng brings a wealth of experience in biopharma partnerships and strategic growth. With his scientific background and expertise in business development, Dr. Zheng will lead global business development and alliance management as we continue advancing transformative antibody therapies in oncology and immunology. Dr. Zheng joins us with a strong track record, including founding Urica Therapeutics and impactful roles at Fortress Biotech and Agenus. We’re excited for the strategic insights he’ll bring as we expand our collaborations and drive our mission forward! Learn more: https://lnkd.in/gpaDXtTS

We’re excited to share that Harbour BioMed has submitted an Investigational New Drug (IND) application for HBM9378/SKB378, a fully human antibody targeting thymic stromal lymphopoietin (TSLP), to the Centre for Drug Evaluation of the National Medical Products Administration of China in the treatment of chronic obstructive pulmonary disease (COPD). This marks a significant milestone as we advance novel therapeutic options for COPD, a condition that deeply impacts patients’ lives. HBM9378/SKB378 is a co-development project conducted by Harbour BioMed and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. It is a fully human monoclonal antibody against TSLP generated from two heavy chains and two light chains (H2L2) Harbour Mice? platform. With fully human sequences, HBM9378/SKB378 offers lower immunogenicity risk and better bioavailability than other TSLP-targeting treatments. Its long half-life and optimized biophysical properties further enhance dosing and formulation advantages. We believe this novel therapy has the potential to meet the diverse needs of COPD patients. Learn more: https://lnkd.in/gPh5PtcZ #HarbourBioMed #COPD #TSLP #innovation

?? We are pleased to announce the online publication of results from our Phase I clinical trial of porustobart (HBM4003), a first-in-class fully human heavy chain antibody targeting CTLA-4, in the Journal for ImmunoTherapy of Cancer (IF=10.3, 2023). This trial evaluated porustobart in combination with the anti-PD-1 antibody toripalimab for treating advanced solid tumors, with a particular focus on melanoma. Data from this multicenter, open-label phase I trial demonstrated that the combination of porustobart and toripalimab had a manageable safety profile, with no new safety signals in the treatment of solid tumors. Initial results also indicated promising antitumor activity, particularly in PD-1 treatment-na?ve mucosal melanoma. Porustobart is the first molecule developed from our HCAb Harbour Mice? platform, paving the way for innovative approaches in cancer immunotherapy. Stay tuned as we continue to explore its potential in addressing unmet medical needs and improving patient outcomes worldwide! The publication is available at: https://lnkd.in/ghvAXDtJ Learn more: https://lnkd.in/g38G3dJj #HarbourBioMed #HCAb #cancer #ClinicalTrial #immunotherapy

We are pleased to share that the latest clinical data on HBM1020, our first-in-class, fully human anti-B7H7/HHLA2 monoclonal antibody for patients with advanced solid tumors, was presented at the ESMO Congress 2024! ??Highlights: ·??????Safety & Tolerability: HBM1020 showed a favorable safety profile across all tested doses. ·??????Promising PK Profiles: HBM1020 demonstrated typical IgG behavior, with drug exposure increasing in a nearly dose-proportional manner. ·??????Preliminary Efficacy: 7 patients (46.7%) achieved stable disease, with two patients showing tumor shrinkage of 11% and 25%. These findings demonstrated excellent safety and tolerability profiles of HBM1020 in patients with advanced solid tumors. We look forward to further studies exploring its therapeutic potential. Learn more: https://lnkd.in/gjY8H8z9 #HarbourBioMed #Oncology #ESMO2024